Veru to Participate in the BTIG Virtual Biotechnology Conference
Oppenheimer Maintains Veru Inc(VERU.US) With Buy Rating, Maintains Target Price $5
Express News | Veru Inc : Jefferies Cuts Target Price to $1 From $1.2
Express News | Veru Presents Phase 2 and 3 Enobosarm Data At ADA Scientific Sessions: Well-Tolerated With Comparable Adverse Event Profile To Placebo; Effective In Reducing Fat And Preserving Lean Mass In Older Adults And Cancer Patients
More Unpleasant Surprises Could Be In Store For Veru Inc.'s (NASDAQ:VERU) Shares After Tumbling 39%
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
Russell 3000: Veru, Life MD Among Consumer Staple Additions; Benson Hill, PetMed Express Among Deletions
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Comstock And 2 Other Stocks Under $2 Insiders Are Buying
Veru Inc(VERU.US) Officer Buys US$5,000 in Common Stock
Veru Inc(VERU.US) Officer Buys US$6,696.5 in Common Stock
Veru Inc(VERU.US) Officer Sells US$87,525.39 in Common Stock
Individual Investors Account for 48% of Veru Inc.'s (NASDAQ:VERU) Ownership, While Institutions Account for 25%
Veru to Present at the Jefferies Global Healthcare Conference
Veru Inc(VERU.US) Officer Buys US$9,999.39 in Common Stock
Veru Inc(VERU.US) Officer Sells US$246.93K in Common Stock
Express News | Veru Announces Steven B. Heymsfield M.d. as the Principal Investigator for Its Enobosarm Phase 2B Clinical Trial for High Quality Weight Loss
Veru Initiated at Buy by B. Riley Securities
Express News | B. Riley Securities Initiates Coverage On Veru With Buy Rating, Announces Price Target of $5
Express News | HC Wainwright & Co. Reiterates Buy on Veru, Maintains $3 Price Target